#1 Clinical Trials Search in Europe

Foscarnet

Foscarnet, also known by its brand name Foscavir, is an antiviral medication that has been the subject of several clinical trials. These studies primarily focus on its use in treating cytomegalovirus (CMV) retinitis, a serious eye infection that can affect people with weakened immune systems, particularly those with AIDS. The trials also explore Foscarnet’s potential in treating other viral infections, such as herpes zoster and herpes simplex virus. This article summarizes the key findings from various clinical trials investigating the efficacy and safety of Foscarnet in different patient populations and treatment regimens.

Table of Contents

What is Foscarnet?

Foscarnet, also known by its brand name Foscavir, is an antiviral medication used to treat various viral infections, particularly in patients with weakened immune systems[1]. It is primarily used in the treatment of cytomegalovirus (CMV) infections and herpes simplex virus (HSV) infections that have not responded to other treatments[2][3].

Conditions Treated with Foscarnet

Foscarnet is used to treat several conditions, including:

  • Cytomegalovirus (CMV) retinitis: An eye infection that can cause vision loss in people with AIDS[1]
  • Herpes zoster: Also known as shingles, a painful rash caused by the varicella-zoster virus[2]
  • Mucocutaneous herpes simplex virus (HSV) infections: Infections affecting the skin, mouth, or genital area in patients who haven’t responded to other treatments[3]
  • Gastrointestinal CMV disease: CMV infections affecting the digestive system[4]

How Foscarnet Works

Foscarnet works by inhibiting viral DNA polymerases, which are enzymes necessary for virus replication. By doing this, it prevents the virus from multiplying and spreading in the body. Importantly, foscarnet does not affect cellular DNA polymerases, which means it targets the virus specifically without interfering with normal cell function[5].

How Foscarnet is Administered

Foscarnet is typically administered in two phases:

  1. Induction therapy: This is the initial phase of treatment, usually lasting 2-4 weeks, where higher doses are given to control the infection[1].
  2. Maintenance therapy: This is the long-term phase, where lower doses are given to prevent relapse[1].

Foscarnet is most commonly given intravenously (through a vein). In some cases, it may be administered at home via a central venous catheter after initial hospital treatment[5]. For certain conditions like herpes simplex infections, a topical cream form of foscarnet may be used[3].

Dosage Information

The dosage of foscarnet varies depending on the condition being treated and the phase of treatment. Some common dosages include:

  • For CMV retinitis:
    • Induction: 60 mg/kg every 8 hours
    • Maintenance: 90-120 mg/kg once daily[1]
  • For herpes zoster: 3g in 250ml, administered intravenously twice daily[2]

It’s important to note that dosages may be adjusted based on individual patient factors and response to treatment.

Clinical Trials and Research

Numerous clinical trials have been conducted to evaluate the efficacy and safety of foscarnet for various conditions. Some key findings include:

  • Foscarnet has shown effectiveness in treating CMV retinitis in AIDS patients, including those who have not responded to or cannot tolerate other treatments like ganciclovir[6].
  • Studies have compared foscarnet to other antiviral medications like ganciclovir for the treatment of CMV retinitis[1].
  • Research has explored the use of foscarnet in treating herpes zoster and comparing its efficacy to acyclovir[2].
  • Some studies have investigated the potential of foscarnet in treating HIV infections, although this is not its primary use[7].

Potential Side Effects

Like all medications, foscarnet can cause side effects. Some potential side effects include:

  • Kidney problems
  • Electrolyte imbalances
  • Nausea and vomiting
  • Headache
  • Fatigue

Your healthcare provider will monitor you closely for these side effects and may adjust your treatment as necessary[8].

Alternatives to Foscarnet

While foscarnet is an important antiviral medication, there are other treatments available for some of the conditions it treats. For example:

  • Ganciclovir: Another antiviral medication used to treat CMV infections. Some studies have compared ganciclovir to foscarnet for treating CMV retinitis[1].
  • Acyclovir: An antiviral medication used to treat herpes simplex and herpes zoster infections. In some cases, foscarnet may be used when acyclovir is not effective[2].

The choice of medication depends on various factors, including the specific condition, the patient’s overall health, and any previous treatments tried. Always consult with your healthcare provider to determine the best treatment option for your situation.

Aspect Details
Primary Uses Treatment of CMV retinitis in AIDS patients, herpes zoster, herpes simplex virus infections
Administration Methods Primarily intravenous; some trials with topical cream
Treatment Regimens Induction therapy followed by maintenance therapy
Comparisons Ganciclovir for CMV retinitis, Acyclovir for herpes zoster
Key Outcomes Measured Efficacy, safety, time to relapse, virus levels in blood/urine, visual function
Advantages Does not cause severe neutropenia, effective in some cases where other antivirals fail
Concerns Potential impact on kidney function, need for proper hydration
Special Populations Immunocompromised patients, particularly those with AIDS

FAQ

  • What is Foscarnet used for in clinical trials? Foscarnet is primarily used in clinical trials to treat cytomegalovirus (CMV) retinitis in AIDS patients. It's also being studied for treating herpes zoster and herpes simplex virus infections in immunocompromised patients.
  • How is Foscarnet administered in these trials? Foscarnet is typically administered intravenously in most trials. Some studies explore different dosing regimens, including induction therapy followed by maintenance therapy. In one trial, a topical cream form of Foscarnet was also studied for herpes simplex virus infections.
  • What are the main outcomes measured in Foscarnet clinical trials? The main outcomes measured include the drug's efficacy in treating the targeted viral infection, time to relapse or recurrence of symptoms, safety profile, and tolerability. Some trials also look at the effect on virus levels in blood and urine, and the impact on visual function in CMV retinitis cases.
  • Are there any comparisons made with other antiviral drugs? Yes, some trials compare Foscarnet to other antiviral drugs. For example, one study compared Foscarnet to Ganciclovir for the initial treatment of CMV retinitis. Another trial compared Foscarnet to intravenous Acyclovir in patients with herpes zoster.
  • What are some potential side effects or concerns with Foscarnet use? While the trials focus on efficacy, they also monitor for side effects. One concern is the impact on kidney function, which is why some studies look at different hydration regimens. Unlike some other antivirals, Foscarnet doesn't seem to cause severe neutropenia (low white blood cell count), which can be beneficial for immunocompromised patients.

Ongoing Clinical Trials on Foscarnet

  • Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

Glossary

  • Cytomegalovirus (CMV) Retinitis: An eye infection caused by the cytomegalovirus that can lead to vision loss. It's a common complication in people with weakened immune systems, especially those with AIDS.
  • Induction Therapy: An initial, more intensive phase of treatment, typically lasting 2-4 weeks, aimed at quickly controlling the infection.
  • Maintenance Therapy: A less intensive, longer-term treatment phase that follows induction therapy, aimed at preventing relapse of the infection.
  • Myelosuppression: A condition where bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets.
  • Neutropenia: A condition characterized by an abnormally low number of neutrophils, a type of white blood cell important for fighting infections.
  • Herpes Zoster: Also known as shingles, it's a viral infection that causes a painful rash, caused by the reactivation of the chickenpox virus.
  • Postherpetic Neuralgia: Lingering pain after a shingles rash has healed, which can last for months or even years.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • HIV p24 Antigen: A protein component of HIV that can be measured in the blood as an indicator of HIV infection and viral activity.

References

  1. https://clinicaltrials.gov/study/NCT00000136
  2. https://clinicaltrials.gov/study/NCT02151240
  3. https://clinicaltrials.gov/study/NCT00002144
  4. https://clinicaltrials.gov/study/NCT00002145
  5. https://clinicaltrials.gov/study/NCT00000726
  6. https://clinicaltrials.gov/study/NCT00002301
  7. https://clinicaltrials.gov/study/NCT00000729
  8. https://clinicaltrials.gov/study/NCT00002125